Abstract
Activation of heterodimeric (αβ) integrin is crucial for regulating cell adhesion. Binding of talin to the cytoplasmic face of integrin activates the receptor, but how integrin is maintained in a resting state to counterbalance its activation has remained obscure. Here, we report the structure of the cytoplasmic domain of human integrin αIIbβ3 bound to its inhibitor, the immunoglobin repeat 21 of filamin A (FLNa-Ig21). The structure reveals an unexpected ternary complex in which FLNa-Ig21 not only binds to the C terminus of the integrin β3 cytoplasmic tail (CT), as previously predicted, but also engages N-terminal helices of αIIb and β3 CTs to stabilize an inter-CT clasp that helps restrain the integrin in a resting state. Combined with functional data, the structure reveals a new mechanism of filamin-mediated retention of inactive integrin, suggesting a new framework for understanding regulation of integrin activation and adhesion.
Similar content being viewed by others
References
Hynes, R.O. Integrins: bidirectional, allosteric signaling machines. Cell 110, 673–687 (2002).
Ye, F., Lagarrigue, F. & Ginsberg, M.H. Snapshot: talin and the modular nature of the integrin adhesome. Cell 156, 1340–1340 e1 (2014).
Bouvard, D., Pouwels, J., De Franceschi, N. & Ivaska, J. Integrin inactivators: balancing cellular functions in vitro and in vivo. Nat. Rev. Mol. Cell Biol. 14, 430–442 (2013).
Kiema, T. et al. The molecular basis of filamin binding to integrins and competition with talin. Mol. Cell 21, 337–347 (2006).
Stossel, T.P. et al. Filamins as integrators of cell mechanics and signalling. Nat. Rev. Mol. Cell Biol. 2, 138–145 (2001).
Das, M., Ithychanda, S.S., Qin, J. & Plow, E.F. Migfilin and filamin as regulators of integrin activation in endothelial cells and neutrophils. PLoS ONE 6, e26355 (2011).
Ithychanda, S.S. et al. Migfilin, a molecular switch in regulation of integrin activation. J. Biol. Chem. 284, 4713–4722 (2009).
Takala, H. et al. β2 integrin phosphorylation on Thr758 acts as a molecular switch to regulate 14-3-3 and filamin binding. Blood 112, 1853–1862 (2008).
Xu, Y. et al. Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J. Exp. Med. 207, 2421–2437 (2010).
Sun, C., Forster, C., Nakamura, F. & Glogauer, M. Filamin-A regulates neutrophil uropod retraction through RhoA during chemotaxis. PLoS ONE 8, e79009 (2013).
Calderwood, D.A. et al. Increased filamin binding to β-integrin cytoplasmic domains inhibits cell migration. Nat. Cell Biol. 3, 1060–1068 (2001).
Ithychanda, S.S. et al. Identification and characterization of multiple similar filamin repeats: implication on filamin-mediated receptor clustering and cross-talking. J. Biol. Chem. 284, 35113–35121 (2009).
Vinogradova, O. et al. A structural mechanism of integrin alpha(IIb)beta(3) “inside-out” activation as regulated by its cytoplasmic face. Cell 110, 587–597 (2002).
Wegener, K.L. et al. Structural basis of integrin activation by talin. Cell 128, 171–182 (2007).
Anthis, N.J. et al. The structure of an integrin/talin complex reveals the basis of inside-out signal transduction. EMBO J. 28, 3623–3632 (2009).
Kim, M., Carman, C.V. & Springer, T.A. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science 301, 1720–1725 (2003).
Lau, T.L., Kim, C., Ginsberg, M.H. & Ulmer, T.S. The structure of the integrin alphaIIbbeta3 transmembrane complex explains integrin transmembrane signalling. EMBO J. 28, 1351–1361 (2009).
Zhu, J. et al. The structure of a receptor with two associating transmembrane domains on the cell surface:integrin alphaIIbbeta3. Mol. Cell 34, 234–249 (2009).
Yang, J. et al. Structure of an integrin αIIbβ3 transmembrane-cytoplasmic heterocomplex provides insight into integrin activation. Proc. Natl. Acad. Sci. USA 106, 17729–17734 (2009).
Choi, W.S. et al. Three-dimensional reconstruction of intact human integrin αIIbβ3: new implications for activation-dependent ligand binding. Blood 122, 4165–4171 (2013).
Goksoy, E. et al. Structural basis for the autoinhibition of talin in regulating integrin activation. Mol. Cell 31, 124–133 (2008).
Song, X. et al. A novel membrane-dependent on/off switch mechanism of talin FERM domain at sites of cell adhesion. Cell Res. 22, 1533–1545 (2012).
Goult, B.T. et al. Structural studies on full-length talin1 reveal a compact auto-inhibited dimer: implications for talin activation. J. Struct. Biol. 184, 21–32 (2013).
Beckerle, M.C., Miller, D.E., Bertagnolli, M.E. & Locke, S.J. Activation-dependent redistribution of the adhesion plaque protein, talin, in intact human platelets. J. Cell Biol. 109, 3333–3346 (1989).
Ma, Y.Q., Qin, J., Wu, C. & Plow, E.F. Kindlin-2 (Mig-2): a co-activator of beta3 integrins. J. Cell Biol. 181, 439–446 (2008).
Peña, E., Padro, T., Molins, B., Vilahur, G. & Badimon, L. Proteomic signature of thrombin-activated platelets after in vivo nitric oxide-donor treatment: coordinated inhibition of signaling (phosphatidylinositol 3-kinase-gamma, 14-3-3zeta, and growth factor receptor-bound protein 2) and cytoskeleton protein translocation. Arterioscler. Thromb. Vasc. Biol. 31, 2560–2569 (2011).
Tu, Y., Wu, S., Shi, X., Chen, K. & Wu, C. Migfilin and Mig-2 link focal adhesions to filamin and the actin cytoskeleton and function in cell shape modulation. Cell 113, 37–47 (2003).
Moik, D.V., Janbandhu, V.C. & Fässler, R. Loss of migfilin expression has no overt consequences on murine development and homeostasis. J. Cell Sci. 124, 414–421 (2011).
Xiao, G. et al. Critical role of filamin-binding LIM protein 1 (FBLP-1)/migfilin in regulation of bone remodeling. J. Biol. Chem. 287, 21450–21460 (2012).
Rantala, J.K. et al. SHARPIN is an endogenous inhibitor of β1-integrin activation. Nat. Cell Biol. 13, 1315–1324 (2011).
Freeman, T.C. Jr. et al. Identification of novel integrin binding partners for calcium and integrin binding protein 1 (CIB1): structural and thermodynamic basis of CIB1 promiscuity. Biochemistry 52, 7082–7090 (2013).
Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277–293 (1995).
Garrett, D.S., Powers, R., Gronenborn, A.M. & Clore, G.M. A common sense approach to peak picking in two-, three-, and four-dimensional spectra using automatic computer analysis of contour diagrams. J. Magn. Reson. 213, 357–363 (2011).
Xu, Y., Wang, X., Yang, J., Vaynberg, J. & Qin, J. PASA: a program for automated protein NMR backbone signal assignment by pattern-filtering approach. J. Biomol. NMR 34, 41–56 (2006).
Schwieters, C.D., Kuszewski, J.J., Tjandra, N. & Clore, G.M. The Xplor-NIH NMR molecular structure determination package. J. Magn. Reson. 160, 65–73 (2003).
Cornilescu, G., Delaglio, F. & Bax, A. Protein backbone angle restraints from searching a database for chemical shift and sequence homology. J. Biomol. NMR 13, 289–302 (1999).
Clore, G.M. & Schwieters, C.D. Docking of protein-protein complexes on the basis of highly ambiguous intermolecular distance restraints derived from 1H/15N chemical shift mapping and backbone 15N-1H residual dipolar couplings using conjoined rigid body/torsion angle dynamics. J. Am. Chem. Soc. 125, 2902–2912 (2003).
Laskowski, R.A., MacArthur, M.W., Moss, D.S. & Thornton, J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26, 283–291 (1993).
Woods, V.L. Jr., Oh, E.H., Mason, D. & McMillan, R. Autoantibodies against the platelet glycoprotein IIb/IIIa complex in patients with chronic ITP. Blood 63, 368–375 (1984).
Acknowledgements
We wish to thank X. Zhang, Y.-Q. Ma, J.-H. Ma and S. Misra for useful discussions and technical assistance. This work was supported by US National Institutes of Health grants to J.Q. (GM062823), V.P.Y. (DK102020) and E.F.P. (HL073311).
Author information
Authors and Affiliations
Contributions
J.L. and J.Q. conceived the study. J.L. performed all NMR and biochemical studies with the assistance of J.Y. and S.S.I. M.D. performed all functional experiments. All authors were involved in data interpretation and discussion. J.L. and J.Q. wrote the manuscript with contributions from all other authors.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Integrated supplementary information
Supplementary Figure 1 Interaction of FLNa-Ig21 with αIIbβ3 CTs.
(a) HSQC of 0.1mM 15N-labeled β3-N in the absence (black) and presence (red) of 0.1mM FLNa-Ig21, pH 6.4, 25°C. (b) Representative real-time sensorgrams of the binding between β3-N and FLNa-Ig21 by SPR analysis (n=2). The real-time binding curves were fitted using a global fitting algorithm to a 1:1 binding model, resulting in the KD~223μM. (c) 2D NOESY fingerprint region of β3-N amides showing sequential NHi-NHi+1 NOEs in the presence of GST-FLNa-Ig21. Note that β3-CT has no binding to GST only (data not shown). (d) Comparison of representative HSQC regions between 15N-labeled FLNa-Ig21 (black) and 15N-labeled FLNa-Ig21-β3-C chimera (red) showing dramatic chemical shift difference consistent with the strong β3-CT binding to FLNa-Ig21 in the chimera. The dramatic spectral perturbation pattern (see the representative peaks) is similar to the slow-exchange FLNa-Ig21 interaction with other strong ligands such as integrin β7-C, migfilin, and GP1bα12. (e). 0.1mM 15N-labeled FLNa-Ig21-β3-C chimera in the absence (black) and presence of 0.2mM β3-N showing significant perturbation of selective residues. (f). 2D NOESY fingerprint region of αIIb-CT showing sequential NHi-NHi+1 NOEs in the presence of GST-FLNa-Ig21. All spectra were performed at 25°C, pH 6.4. (g). 2D NOESY fingerprint region of αIIb-CT showing K989-F992 Hαi-NHi+3 and Hαi-Hβi+3 NOEs in the presence of GST-FLNa-Ig21.
Supplementary Figure 2 FLNa-Ig21 promotes ternary-complex formation with αIIb CT and β3 CT.
(a) Representative real-time sensorgrams of the binding between αIIb-CT and β3-CT by SPR analysis (n=2). The real-time binding curves were fitted using a global fitting algorithm to a 1:1 binding model, resulting in the KD~368μM. (b) Chemical shift perturbation profiles of 0.1mM 15N-labeled FLNa-Ig21 by 0.03mM β3-CT (top panel) and 0.03mM β3-CT L717K/L718K mutant (bottom panel) showing that the mutations did not affect the FLNa-Ig21/β3-CT interaction. Note that lower amount of WT β3-CT had to be used to reduce the line-broadening problem and perform the chemical shift mapping as compared to that of the β3-CT mutant. (c) HSQC of 0.1mM 15N-labeled 0.1mM β3-CT L717K/L718K mutant in the absence (black) and presence (red) of 0.1mM FLNa-Ig21 showing substantially reduced line-broadening problem as compared to Fig. 1A (upper panel), which allowed the chemical shift mapping of both perturbed β3-MP and β3-C regions (lower panel). (d) HSQC of 0.1mM 15N-labeled β3-CT L717K/L718K mutant in the absence (black) and presence (red) of 0.1mM FLNa-Ig21 and presence of 0.1mM FLNa-Ig21+0.2mM αIIb-CT (green) showing that αIIb-CT induced further chemical shift changes of β3-CT bound to FLNa-Ig21. (e) Representative intermolecular NOE strips: left panel, NOEs between FLNa-Ig21 and αIIb-CT; right panel, NOEs between between FLNa-Ig21 and β3-CT.
Supplementary Figure 3 Critical side chain interface of FLNa-Ig21–αIIb CT–β3 CT complex.
Overlay of 20 lowest energy structures showing the side chain convergence of critical interface residues as shown in Fig 3.
Supplementary Figure 4 Mutation effects of FLNa-Ig21–αIIb CT–β3 CT ternary complex.
(a) Chemical shift perturbation profiles of αIIb-CT in the presence of FLNa-Ig21 (upper panel) vs FLNa-Ig21 E2276A (lower panel) showing that the E2276A mutation impaired the FLNa-Ig21/αIIb-CT interaction. (b) Chemical shift perturbation profiles of β3-CT L717K/L718K in the presence of FLNa-Ig21 (upper panel) vs FLNa-Ig21 E2276A (lower panel) showing that the E2276A mutation has little effect on the FLNa-Ig21/β3-CT interaction. (c) HSQC of 0.1 mM 15N-labeled FLNa-Ig21 in the absence (black) and presence (red) of 0.2mM αIIb CT K994E/R997E mutant showing that the mutation diminished the FLNa-Ig21/αIIb CT interaction. (d) Transferred NOEs in the selected region of NOESY for 2mM aIIb K994E/R997E mutant in the absence (no NOEs) and presence (black) of 0.1mM MBP-β3 CT showing the αIIb/β3 CT interaction is preserved as shown for the WT αIIb CT previously13. (e) Chemical shift perturbation profile of 0.1mM 15N-labeled FLNa-Ig21 in the presence of β3-N (upper panel) vs FLNa-Ig21 A2268K in the presence of β3-N (lower panel) showing that the A2268K mutation impaired the FLNa-Ig21/β3-N interaction. (f). Chemical shift perturbation profile of 0.1mM 15N-labeled FLNa-Ig21 in the presence of 0.2mM αIIb-CT (upper panel) vs FLNa-Ig21 A2268K in the presence of αIIb-CT (lower panel) showing that the A2268K mutation has little effect on the FLNa-Ig21/αIIb-CT interaction. (g). FLNa-Ig21 expression is similar to F21EA and F21AK mutants (no statistically significant difference). Data represent 3 independent experiments and error bars indicate Mean±S.E.M as explained in the legend for Fig 5.
Supplementary Figure 5 Interaction of FLNa repeats with αIIb CT and β3-N.
(a) 0.1mM 15N-labeled FLNa-Ig9 with 0.5mM αIIb CT and (b) with 0.5mM β3-N. (c) 0.1mM 15N-labeled FLNa-Ig12 with 0.2mM αIIb CT and (d) with 0.2mM β3-N. (e). 0.1mM 15N-labeled FLNa-Ig17 with 0.2mM αIIb CT and (f) with 0.2mM β3-N. (g) 0.1mM 15N-labeled FLNa-Ig19 with 0.2mM αIIb CT and (h) with 0.2mM β3-N. All spectra show the interaction as judged by the selective chemical shift changes. Note that higher ratio of αIIb CT or β3-N was used due to their weaker interaction with FLNa-Ig9.
Supplementary Figure 6 Comparison of several αIIbβ3 CT complex structures.
(a). Structure of αIIbβ3 TMCD determined in bicelles17. The dotted box indicates the membrane-proximal clasp that was shown to be embedded in the membrane17, which is inaccessible to cytosolic binding proteins. The region in red highlights the reverse turn conformation. This red region corresponds to the red region in (b)-(d). (b) αIIbβ3 CT complex bound to FLNa-Ig21 with αIIb membrane-proximal region being helical. (c) Overlay of the membrane-proximal clasp between the structure in (b) and a previous structure (PDB 1M8O13). (d) Overlay of the membrane-proximal clasp between the structure in (b) and another previous structure (PDB 2KNC19).
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–6 and Supplementary Table 1 (PDF 1744 kb)
Supplementary Data Set 1
Supplementary Data Set 1 (PDF 39 kb)
Rights and permissions
About this article
Cite this article
Liu, J., Das, M., Yang, J. et al. Structural mechanism of integrin inactivation by filamin. Nat Struct Mol Biol 22, 383–389 (2015). https://doi.org/10.1038/nsmb.2999
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nsmb.2999
- Springer Nature America, Inc.
This article is cited by
-
The structural basis of β2 integrin intra-cellular multi-protein complexes
Biophysical Reviews (2022)
-
Septo-optic dysplasia caused by a novel FLNA splice site mutation: a case report
BMC Medical Genetics (2019)
-
Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting
Journal of Hematology & Oncology (2019)
-
Integrin α11 cytoplasmic tail is required for FAK activation to initiate 3D cell invasion and ERK-mediated cell proliferation
Scientific Reports (2019)
-
Costameres, dense plaques and podosomes: the cell matrix adhesions in cardiovascular mechanosensing
Journal of Muscle Research and Cell Motility (2019)